RxDoctor Payments Data

Stephen Bauer, MD

Vascular Surgery · Stamford, CTNPI 1477610913

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (38.8%), other and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Philips North America LLC at 41.3% of the total. Reporting peaked in 2019 at $18,885 and has fallen 65.0% since, to $6,608 in 2025.

$44,802in general payments, 2019–2025

Across 252 payments — averaging $177.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$18K
  • Angiodynamics, Inc.$14K
  • Medtronic$5K
  • Endologix LLC$2K
  • Bard Peripheral Vascular, Inc.$1K
  • Boston Scientific$697
  • plus $3K from 18 others

What the payments were for

  • Speaking & faculty fees$17,40039%
  • Food & beverage$13,15329%
  • Education$380%
  • Other$14,21132%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,802 in reported general payments places this provider in the 80th percentile of 82 vascular surgery providers in Connecticut.

See all vascular surgery providers in Connecticut

Medicare billing

Part B allowed, 2024
$1,050,077
Medicare patients
526
Services billed
5,892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban95$90,753
EliquisApixaban21$22,987
Cilostazol24$486
ClopidogrelClopidogrel Bisulfate49$423
Doxycycline Hyclate13$123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$639$90,75395 claims
PfizerEliquis$192$22,98721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 82 vascular surgery providers in Connecticut.

Other vascular surgery in Stamford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →